BIRC5 and cancer: More recently, Andersen, et al. demonstrated that wild type survivin-derived Sur20-28 peptide (amino acid sequence STFKNWPFL) was capable of inducing the peptide-specific CD8-positive T-cells from PBMCs of HLA-A24+ cancer patients, although HLA-A24-restricted killing activity of the peptide-specific T-cells against survivin-positive cancer cells has not been assessed [32].